Finance and Accounting
Charles E. Gillman Company
Accounting Specialist Sales and Marketing
Everready Glass
Sales Reps Health Care
CENTRAL ARIZONA COLLEGE
DIRECTOR OF HEALTH INFORMATION MANAGEMENT Mechanical
Komatsu Equipment Co
Resident Field Mechanic Construction
West-Press
Printing Health Care
Sierra Tucson
Eating Disorders Program Coordinator Administrative & Professional
Jorgensen Brooks Group
Counselor

Tucson-based ImaRx Therapeutics Inc., a drug developer that went public in July, said it narrowed its second-quarter loss as revenues rose on sales of a drug that breaks up blood clots.

The company reported a net loss of $1.5 million, or 74 cents per share, in the second quarter compared with a net loss of about $4.1 or $1.62 per share in the second quarter last year.

The results include non-cash charges for accretion of preferred stock dividends totaling $434,000 in the second quarter of this year and $150,000 in the second quarter a yearr ago.

Second-quarter revenue was $2.2 million, compared with revenue of approximately $300,000 in the second quarter of 2006. The company attributed the increase to $2 million in sales of Abbokinase, a clot-busting drug ImaRx acquired last year from Abbott Laboratories.

ImaRx shares closed up 3 cents, at $3.78 per share, in trading Thursday on the Nasdaq Capital Market. The shares have closed as high as $4.80 since the company went public July 26.